Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ranibizumab biosimilar by Shanghai Biomabs Pharmaceuticals for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval
Ranibizumab biosimilar is under clinical development by Shanghai Biomabs Pharmaceuticals and currently in Phase I for Wet (Neovascular / Exudative)...
Ranibizumab biosimilar by Incepta Pharmaceuticals for Diabetic Macular Edema: Likelihood of Approval
Ranibizumab biosimilar is under clinical development by Incepta Pharmaceuticals and currently in Phase III for Diabetic Macular Edema. According to...
Ranibizumab biosimilar by Generium for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval
Ranibizumab biosimilar is under clinical development by Generium and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration....